HC Wainwright Cuts ALX Oncology (NASDAQ:ALXO) Price Target to $5.00

ALX Oncology (NASDAQ:ALXOFree Report) had its target price reduced by HC Wainwright from $25.00 to $5.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for ALX Oncology’s FY2029 earnings at $0.63 EPS.

A number of other equities analysts also recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research note on Wednesday, December 18th. Jefferies Financial Group cut ALX Oncology from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $12.00 to $2.00 in a research note on Thursday, December 19th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, ALX Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $3.50.

Check Out Our Latest Report on ALX Oncology

ALX Oncology Trading Down 7.1 %

NASDAQ ALXO opened at $1.52 on Friday. The company’s 50-day simple moving average is $1.62 and its two-hundred day simple moving average is $2.36. ALX Oncology has a one year low of $1.19 and a one year high of $17.83. The company has a market capitalization of $79.91 million, a price-to-earnings ratio of -0.51 and a beta of 0.98. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82.

Insider Transactions at ALX Oncology

In related news, Director Rekha Hemrajani acquired 30,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was purchased at an average cost of $1.55 per share, with a total value of $46,500.00. Following the transaction, the director now directly owns 33,000 shares of the company’s stock, valued at $51,150. This trade represents a 1,000.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 14,443 shares of company stock valued at $23,309. Corporate insiders own 33.40% of the company’s stock.

Institutional Trading of ALX Oncology

Several large investors have recently bought and sold shares of ALXO. Barclays PLC raised its stake in shares of ALX Oncology by 243.6% in the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after purchasing an additional 42,185 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in ALX Oncology during the 2nd quarter worth approximately $1,834,000. GSA Capital Partners LLP purchased a new position in ALX Oncology during the 3rd quarter worth approximately $88,000. Marshall Wace LLP lifted its stake in ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock valued at $3,833,000 after acquiring an additional 514,133 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after acquiring an additional 6,888 shares during the last quarter. Hedge funds and other institutional investors own 97.97% of the company’s stock.

About ALX Oncology

(Get Free Report)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.

Recommended Stories

Analyst Recommendations for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.